ReviewFrontiers in oncology2026
RBBP6 and cancer: from molecular mechanisms to clinical implications.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma binding protein 6 (RBBP6) is a 200 kDa E3 ubiquitin ligase that performs several biological functions and plays a role in tumorigenesis. RBBP6 is overexpressed in several types of tumors, including lung, colorectal, breast, cervical, hepatocellular, and esophageal cancers, suggesting its association with malignant progression. Moreover, this increased expression has been associated with clinicopathological parameters in lung, colorectal, cervical, and ovarian cancers. This review captures the molecular functions of RBBP6 and the mechanisms by which aberrant RBBP6 expression and function influence cancer development and therapeutic response. These mechanisms include its ability to interact with E3 ligase substrates, Jun N-terminal kinase (JNK), noncoding RNAs, and DNA damage-associated proteins to promote cell proliferation, stemness, cell cycle progression, and metastasis. We also evaluated the prognostic and predictive significance of RBBP6 as a potential cancer biomarker and its suitability as a molecular target in cancer. This is the first review that comprehensively explores the multifaceted molecular mechanisms by which RBBP6 influences cancer progression in several cancer types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.